Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | KLK1 | P06870 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6698438 | 1.00 | F10 (0.75) | F10KCNH2KLK1 | |
| SCHEMBL7002874 | 0.86 | F10 (1.00) | F10KCNH2KLK1 | |
| SCHEMBL6698415 | 0.84 | KCNH2 (0.57) | F10KCNH2KLK1 | |
| SCHEMBL6698420 | 0.84 | KCNH2 (0.57) | F10KCNH2KLK1 | |
| SCHEMBL6697452 | 0.81 | F10 (0.87) | F10KCNH2KLK1 | |
| SCHEMBL5327935 | 0.80 | F10 (0.71) | F10KCNH2 | |
| SCHEMBL6697112 | 0.79 | F10 (0.79) | F10KCNH2KLK1 | |
| SCHEMBL6692670 | 0.78 | F10 (0.87) | F10KCNH2 | |
| SCHEMBL6698359 | 0.78 | F10 (0.85) | F10KCNH2KLK1 | |
| SCHEMBL6703106 | 0.77 | F10 (0.86) | F10KCNH2KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072860-A1 | Piperazin-2-one amides as inhibitors of factor xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-15 | — | — | US | disclosed |
| EP-1322643-A1 | PIPERAZIN-2-ONE AMIDES AS INHIBITORS OF FACTOR XA | Millennium Pharmaceuticals, Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002026734-A1 | PIPERAZIN-2-ONE AMIDES AS INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072860-A1 | Piperazin-2-one amides as inhibitors of factor xa | F2, TFPI, TFPI2 | F10 12/4885KCNH2 2157/4885KLK1 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.